T1	Participants 105 174	in patients with acute myeloid leukemia and myelodysplastic syndromes
T2	Participants 178 227	Japanese multicenter randomized, controlled study
T3	Participants 378 488	in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy
T4	Participants 710 782	In patients with MDS or in the remission-induction phase of chemotherapy
T5	Participants 1298 1351	in patients with AML or MDS who received chemotherapy
